X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Biocon Ltd Fact Sheet, Biocon Ltd Financial Results - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Biocon Ltd Fact Sheet   (BICN)

Here is the latest financial fact sheet of Biocon Ltd. For more details, see the Biocon Ltd quarterly results and Biocon Ltd share price and chart. For a sector overview, read our pharmaceuticals sector report.

BIOCON LTD Price History

Price Rs 423.0
Mkt Cap Rs m 253,800
Vol '000 755.1
P/E X 55.7
P/CF X 20.9
EPS (TTM) Rs 7.6
% ch % 7.3
No. of shares m 600.00
% ch week % 12.0
% ch 1-mth % 16.4
% ch 12-mth % 49.1
52 week H/L Rs 424.9/279.1
(As on Nov 20, 2017 (Close))
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

BIOCON LTD Financials

No. of Mths
Year Ending
12
Mar-12
*
12
Mar-13
*
12
Mar-14
*
12
Mar-15
*
12
Mar-16
*
5-Yr Chart
Click to enlarge
BIOCON LTD EQUITY SHARE DATA
High Rs385307497554496 
Low Rs243211265407397 
Sales per share (Unadj.) Rs104.3124.3143.9154.5174.3 
Earnings per share (Unadj.) Rs16.925.420.724.944.8 
Diluted earnings per shareRs5.68.56.98.314.9 
Cash flow per share (Unadj.) Rs25.634.430.935.956.9 
Dividends per share (Unadj.) Rs5.007.505.005.005.00 
Adj. dividends per shareRs1.672.501.671.671.67 
Dividend yield (eoy) %1.62.91.31.01.1 
Book value per share (Unadj.) Rs113.6134.7151.3163.5202.8 
Adj. book value per shareRs37.944.950.454.567.6 
Shares outstanding (eoy) m200.00200.00200.00200.00200.00 
Bonus/Rights/Conversions  ----- 
Price / Sales ratio x3.02.12.63.12.6 
Avg P/E ratio x18.610.218.419.310.0 
P/CF ratio (eoy) x12.27.512.313.47.8 
Price / Book Value ratio x2.81.92.52.92.2 
Dividend payout %29.629.524.220.111.2 
Avg Mkt Cap Rs m62,80051,79076,19096,08089,220 
No. of employees `0006.36.77.37.54.4 
Total wages/salary Rs m3,0763,8944,6635,3346,363 
Avg. sales/employee Rs Th3,336.83,694.53,936.14,119.77,894.5 
Avg. wages/employee Rs Th491.9578.9637.9711.21,441.2 
Avg. net profit/employee Rs Th541.2756.5566.1663.22,029.7 
BIOCON LTD INCOME DATA
Net Sales Rs m20,86524,85328,77330,89834,854 
Other income Rs m618527559531845 
Total revenues Rs m21,48325,38029,33231,42935,699 
Gross profit Rs m5,1735,4306,8716,9588,200 
Depreciation Rs m1,7441,7932,0362,2102,423 
Interest Rs m122811789102 
Profit before tax Rs m3,9254,0835,3775,1906,520 
Minority Interest Rs m0-38-170-310-744 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m02,01901,0515,754 
Tax Rs m5419751,0699572,569 
Profit after tax Rs m3,3845,0894,1384,9748,961 
Gross profit margin %24.821.823.922.523.5 
Effective tax rate %13.823.919.918.439.4 
Net profit margin %16.220.514.416.125.7 
BIOCON LTD BALANCE SHEET DATA
Current assets Rs m19,99722,40026,38825,62639,932 
Current liabilities Rs m10,1589,89913,79615,54716,276 
Net working cap to sales %47.250.343.832.667.9 
Current ratio x2.02.31.91.62.5 
Inventory Days Days6659485354 
Debtors Days Days8675769186 
Net fixed assets Rs m16,60018,22827,30833,06539,101 
Share capital Rs m1,0001,0001,0001,0001,000 
"Free" reserves Rs m20,74524,07927,04730,77838,591 
Net worth Rs m22,72426,94630,26732,70640,556 
Long term debt Rs m6981,6406,0627,69620,724 
Total assets Rs m39,37244,16157,50663,75484,816 
Interest coverage x33.251.4317.359.364.9 
Debt to equity ratio x00.10.20.20.5 
Sales to assets ratio x0.50.60.50.50.4 
Return on assets %8.911.77.27.910.7 
Return on equity %14.918.913.715.222.1 
Return on capital %17.321.514.414.919.0 
Exports to sales %31.938.037.133.530.7 
Imports to sales %21.522.422.819.720.4 
Exports (fob) Rs m6,6619,45010,66910,33910,717 
Imports (cif) Rs m4,4815,5616,5736,1027,105 
Fx inflow Rs m6,7739,90610,80310,99311,789 
Fx outflow Rs m5,4496,3307,7157,3718,393 
Net fx Rs m1,3243,5763,0883,6223,396 
BIOCON LTD CASH FLOW
From Operations Rs m 5,641 4,712 5,607 2,107 5,264 
From Investments Rs m -3,595 -3,758 -9,381 -5,087 -9,540 
From Financial Activity Rs m -1,863 -86 4,260 1,862 10,867 
Net Cashflow Rs m 183 868 486 -1,118 6,591 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 40.4%
Foreign collaborators 20.6%
Indian inst/Mut Fund 8.4%
FIIs 10.7%
ADR/GDR 0.0%
Free float 19.9%
Shareholders 109,995
Pledged promoter(s) holding 0.0%
 

Company Information

REGD OFF 20th KM, Hosur Road, Electronic City, Bangalore - 560 100
E-MAIL kiran.kumar@biocon.com WEB www.biocon.com
TELEPHONE (080) 2808 2037 FAX (080) 2852 3423
SECTOR PHARMACEUTICALS GROUP MISCELLANEOUS
TR AGENT Karvy Computershare, 17-24, Vithalrao Nagar, Madhapur, Hyderabad-81
AUDITOR S. R. Batliboi & Assoc.
CHM: Kiran Mazumdar Shaw (MD) COMP SEC: Kiran Kumar YEAR OF INC: 1978 BSE CODE: 532523 FV (Rs): 5 DIV YIELD (%): 0.4

More Pharmaceuticals Company Fact Sheets:   ASTRAZENECA PHARMA  ALEMBIC LTD  SUVEN LIFE  DIVIS LABORATORIES  ALEMBIC PHARMA  

Compare BIOCON LTD With:   ASTRAZENECA PHARMA  ALEMBIC LTD  SUVEN LIFE  DIVIS LABORATORIES  ALEMBIC PHARMA  

Compare BIOCON LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Dull Start to the Week; Cement Stocks Tank(Closing)

Indian share markets continued to trade on a dull note in the afternoon session amid weak international markets.

Views on news

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

'Buy and Hold Forever' Not The Best Investing Style After All(The 5 Minute Wrapup)

Nov 9, 2017

Even Buffett didn't always Buy and Hold forever. A look at Berkshire's 1992 and 2017 portfolios will tell you the story...

Of Falling Real Estate Prices, Dr Arvind Panagariya and the Art of Continuing to Suck Up(Vivek Kaul's Diary)

Nov 13, 2017

Dr Panagariya claims real estate prices have fallen 25 per cent post demonetisation; the official data doesn't show anything like that.

You're Lucky You Missed Out on that IPO...(Smart Contrarian)

Nov 8, 2017

Here's how to profit from upcoming IPOs.

Your Last Chance to Trade ONLY the Best Stocks(Daily Profit Hunter)

Nov 11, 2017

Techno-Funda opportunities are knocking on your door. Are you ready to receive them?

Why I am the Biggest India Equity Bull on Planet Earth!(The Honest Truth)

Nov 16, 2017

If you have a dream, dream big...about the level of BSE 30 index in 2050!

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK BIOCON LTD

  • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON BIOCON LTD

BIOCON LTD - UNICHEM LAB COMPARISON

COMPARE BIOCON LTD WITH

MARKET STATS